GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2012

M&A Activity in 2012 Will Surpass Last Year’s Pace, GEN Online Readers Predict

  • A more than 3-to-1 majority of GEN online readers believe that M&A activity among drug developers in 2012 will surpass that of 2011. Voting 70.7% to 20.7%, with 8.6% undecided, respondents offered a sunny forecast for mergers and acquisitions among biopharmaceutical companies. While M&A activity was strong in 2011, the number of those huge blockbuster agreements seemed to be lower. Sanofi topped last year’s list of biggest M&A deals with its $20.1 billion buy of Genzyme—about half of the $41 billion that 2010’s top-spender, Novartis, paid for Alcon. The top-five list for 2011 ended with Forest Laboratories’ $1.2 billion purchase of Clinical Data, while last year the fifth place went to Daiichi Sankyo when it bought Ranbaxy for $4.6 billion.

     

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?